Like the analysis of KEYNOTE studies by CGP (4) and WES (5) leading to the pan-solid tumor approval of pembrolizumab in the >first-line setting (29), which did not assess all possible tumor types but observed relatively consistent pembrolizumab monotherapy benefit in TMB-H patients across tumor types, results from our current study further support the pan-solid tumor predictive nature of IRS-H status for anti-PD-(L)1 monotherapy benefit (20). The gene discussed is CD274; the disease is neoplasm.